Zimmer Biomet Holdings Company Profile (NYSE:ZBH)

Zimmer Biomet Holdings trades on the New York Stock Exchange (NYSE) under the ticker symbol "ZBH."

Zimmer Biomet Holdings declared a quarterly dividend on Tuesday, May 30th. Stockholders of record on Friday, June 23rd will be paid a dividend of $0.24 per share on Friday, July 28th. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.77%. The ex-dividend date of this dividend is Wednesday, June 21st. View Zimmer Biomet Holdings' Dividend History.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) announced its earnings results on Thursday, July, 27th. The company reported $2.08 earnings per share for the quarter, missing the Zacks' consensus estimate of $2.10 by $0.02. The company earned $1.95 billion during the quarter, compared to analyst estimates of $1.95 billion. Zimmer Biomet Holdings had a return on equity of 16.80% and a net margin of 6.36%. Zimmer Biomet Holdings's quarterly revenue was up 1.1% compared to the same quarter last year. During the same period in the prior year, the business earned $2.02 earnings per share. View Zimmer Biomet Holdings' Earnings History.

Zimmer Biomet Holdings is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for Zimmer Biomet Holdings.

Zimmer Biomet Holdings issued an update on its FY17 earnings guidance on Thursday, July, 27th. The company provided earnings per share (EPS) guidance of $8.20-8.30 for the period, compared to the Thomson Reuters consensus EPS estimate of $8.51. The company issued revenue guidance of $7.8-7.87 billion, compared to the consensus revenue estimate of $7.86 billion.Zimmer Biomet Holdings also updated its Q3 guidance to $1.72-1.77 EPS.

23 brokers have issued 1-year target prices for Zimmer Biomet Holdings' shares. Their predictions range from $92.00 to $158.00. On average, they expect Zimmer Biomet Holdings' share price to reach $139.57 in the next twelve months. View Analyst Ratings for Zimmer Biomet Holdings.

Here are some recent quotes from research analysts about Zimmer Biomet Holdings stock:

• 1. According to Zacks Investment Research, "Over the last three months, Zimmer Biomet was trading below the Zacks categorized Medical Product industry on factors like macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations. Situation deteriorated further with the company lowering a disappointing 2017 outlook. According to the company, lower-than-expected manufacturing output of certain legacy Biomet brands during the first quarter 2017 which may lead to declining product availability in the second quarter, required Zimmer Biomet to lower its guidance. However, we are hopeful about the synergy from LDR Holding buyout, which should complement the company’s musculoskeletal offering. Emerging market expansion is another upside." (7/4/2017)
• 2. Canaccord Genuity analysts commented, "SGEN reported 1Q earnings and provided a pipeline update." (4/28/2017)
• 3. Needham & Company LLC analysts commented, "We hosted a dinner and investor meetings with Dan Florin, Senior Vice President and CFO, and Bob Marshall, Treasurer and Vice President of Investor Relations this week in New York City. We think that the discussion was upbeat and highlighted ZBH's progress in addressing its manufacturing challenges, its non-recon business performance, margin opportunities, and cash flow outlook. The meetings reinforced our view that ZBH should be able to drive its revenue growth to sustainable mid-single digit growth with a combination of market growth in recon and above-market growth in its non-recon businesses. We reiterate our Strong Buy rating." (2/17/2017)
• 4. J P Morgan Chase & Co analysts commented, "Zimmer’s re-acceleration continued into 2Q earnings as sales grew 4.5% pro- forma and 2.6% organic excluding an extra selling day. Organic growth came in well above the Street’s call for 1.6% organic growth and buy-side calls for 1.9% (see our recent survey here). The sales beat was broad based with each business performing in-line or better than Street estimates with Knees (+$2M), Hips (+$9M), SET (+$20M), and Dental (+$5M) as the standout performers in the quarter. While gross margins were lower than expected (70bps), this was tempered by in-line operating expense and a better than expected tax rate including benefits from the early adoption of ASU 2016-09 (+$0.01). When factoring in the better than expected top-line, this drove a $0.05 Cash EPS beat. With Zimmer’s turnaround tracking ahead of expectations, we reiterate our Overweight rating on the stock and raise our price target from $134 to $148 (Y/E 17), conservatively valuing the stock at 15x 2018 Cash EPS, a 20% discount to its peers." (7/29/2016)

Some companies that are related to Zimmer Biomet Holdings include Baxter International (BAX), C R Bard (BCR), DENTSPLY SIRONA (XRAY), Align Technology (ALGN), Bio-Rad Laboratories (BIO), Steris Plc (STE), West Pharmaceutical Services (WST), DexCom (DXCM), Hill-Rom Holdings (HRC), VWR Corporation (VWR), NuVasive (NUVA), Integra LifeSciences Holdings Corporation (IART), ICU Medical (ICUI), LivaNova PLC (LIVN), Nevro Corp. (NVRO), Neogen Corporation (NEOG), Haemonetics Corporation (HAE) and Inogen (INGN).

Zimmer Biomet Holdings' management team includes the folowing people:

• Daniel P. Florin, Interim Chief Executive Officer, Chief Financial Officer, Director
• Robert D. Delps, President, Americas
• Katarzyna Mazur-Hofsaess M.D. Ph.D., President, Europe, Middle East and Africa
• Sang Yi, President, Asia Pacific
• Chad F. Phipps, Senior Vice President, General Counsel, Secretary
• Larry C. Glasscock, Independent Non-Executive Chairman of the Board
• Christopher B. Begley, Independent Director
• Betsy J. Bernard, Independent Director
• Gail Koziara Boudreaux, Independent Director
• Michael Farrell, Independent Director

Zimmer Biomet Holdings' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Longview Partners Guernsey LTD (3.16%), Harbour Capital Advisors LLC (0.65%), Focused Investors LLC (0.57%), Factory Mutual Insurance Co. (0.26%), Russell Investments Group Ltd. (0.26%) and Hexavest Inc. (0.15%). Company insiders that own Zimmer Biomet Holdings stock include Blackstone Capital Partners V, Chad F Phipps, Daniel E Williamson, Daniel P Florin, David A Jr Nolan, David C Dvorak, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Institutional Ownership Trends for Zimmer Biomet Holdings.

Zimmer Biomet Holdings' stock was sold by a variety of institutional investors in the last quarter, including Focused Investors LLC, Sit Investment Associates Inc., APG Asset Management N.V., Russell Investments Group Ltd., Great West Life Assurance Co. Can, Affinity Investment Advisors LLC, Hexavest Inc. and Exxonmobil Investment Management Inc. TX. Company insiders that have sold Zimmer Biomet Holdings stock in the last year include Chad F Phipps, Daniel E Williamson, David A Jr Nolan, David C Dvorak, Sang Yi, Stuart G Kleopfer and Tony W Collins. View Insider Buying and Selling for Zimmer Biomet Holdings.

Zimmer Biomet Holdings' stock was purchased by a variety of institutional investors in the last quarter, including Harbour Capital Advisors LLC, Longview Partners Guernsey LTD, Ferguson Wellman Capital Management Inc., Bank of Montreal Can, Mn Services Vermogensbeheer B.V., BTIM Corp., National Pension Service and ING Groep NV. View Insider Buying and Selling for Zimmer Biomet Holdings.

Shares of Zimmer Biomet Holdings can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Zimmer Biomet Holdings stock can currently be purchased for approximately $125.44.